I will caveat there is some seasonal noise that comes with the producing rep count. You tend to see some quarters a little bit higher, a little bit lower, not reflecting turnover or adds but just showing some seasonal changes there. The other part of that as we mentioned on a previous call, that we do really empower our sales force to build the most effective team to represent our portfolio and best be a service to our surgeon customers. And so you sometimes have some of our sales force finding ways to represent the 80 different product families we’ve launched in the most meaningful way, and you’ll see some noise with that as well.
Stephen Deitsch: Yes. Craig.. I would just add to that, that the best leading indicator that we are aware of to predict producing reps in the future is the overall growth in our sales force. And our commercial team has done just a terrific job of expanding our feet on the street in almost every geography in the U.S. with both talented experienced reps and also reps new of the foot and ankle industry, who we expect to have the ability to become producing reps in the future. So when you think about our producing rep count at 200, that is not a significant increase, as I’m sure you’re aware year-over-year. But what we expect in the future, ’23, ’24, ’25 is all of these investments we’ve made to really drive that producing rep count and also continue to drive growth for us as a major lever of growth in those years.
Albert DaCosta: And one more comment that I’ll make on that is, I feel like every product we launch generates some attraction to a whole new subset of salespeople looking for different pieces of technology and really one of the most comprehensive portfolios in foot and ankle. So the spotlight being a public company is something we’ve mentioned has been really beneficial to Paragon. And I feel like that on top of the products we’re launching is just — we’ve got a really good energy around the sales force right now.
Craig Bijou: And I was hoping you could expand a little bit on your comments on the international growth that you’ve seen. And obviously, it’s been strong but how big of a growth driver is it for, call it the next 3 to 5 years? And what does that actually entail? I mean, how — I know you’re — you’ve called out the markets that are very strong and you’re going deeper there. But does it also entail expanding into other international markets? And really just kind of want to understand how big a piece of the future growth the international side is.
Stephen Deitsch: No, Craig, it’s really an area that we’re excited about as well to drive our future growth. We’ve put a really great team across all of Europe, whether you’re looking at the head of sales, you’re looking at the head of medical education. We built out really strong infrastructure to support not only the markets that we’re in today, but new markets. And so, we are expanding into new markets, and I’ll touch on those in just a moment. But I would tell you that our growth right now is really being driven by these amazing teams in the U.K. We’ve recently added some terrific folks there that are really bringing a revitalization to the U.K. market. That BigFoot meeting that Albert talked about with — I don’t remember the exact number of surgeons, well over 100 in attendance, current customers and a lot of new customers potentially.